Beam Therapeutics CEO John M. Evans reports sale of $1.19 million in common shares
BEAM•Beam Therapeutics CEO and director John M. Evans sold 50,000 common shares on October 15 and 16, 2026, for a total of about $1.19 million.
1. Share sale details
Evans sold 25,000 shares at $23.566 on October 15 and another 25,000 at $23.9838 on October 16. He exercised options for 25,000 shares on each date at $1.03 per share; after the transactions, he held 1,047,205 shares directly and 103,000 indirectly through a trust, with 155,804 directly held options remaining at an exercise price of $1.03.
